000283122 001__ 283122
000283122 005__ 20260105130452.0
000283122 0247_ $$2pmid$$apmid:41485137
000283122 0247_ $$2doi$$a10.1002/alz.71064
000283122 0247_ $$2ISSN$$a1552-5260
000283122 0247_ $$2ISSN$$a1552-5279
000283122 037__ $$aDZNE-2026-00018
000283122 041__ $$aEnglish
000283122 082__ $$a610
000283122 1001_ $$aZhu, Zeyu$$b0
000283122 245__ $$aDefining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease
000283122 260__ $$aHoboken, NJ$$bWiley$$c2026
000283122 3367_ $$2DRIVER$$aarticle
000283122 3367_ $$2DataCite$$aOutput Types/Journal article
000283122 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767601555_32742
000283122 3367_ $$2BibTeX$$aARTICLE
000283122 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283122 3367_ $$00$$2EndNote$$aJournal Article
000283122 520__ $$aAmyloid-induced tauopathy drives clinical decline in Alzheimer's disease (AD). Because age and sex shape tau trajectories, defining patient-centered amyloid thresholds for tauopathy onset could facilitate pre-tauopathy AD identification and aid treatment decisions and prognosis.By including two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI, n = 301]; and 18F-AV-1451-A05 [A05, n = 143]), we explored whether age and sex affect tauopathy transition and determined patient-centered amyloid positron emission tomography (PET) thresholds that mark tauopathy onset.We found a consistent amyloid PET × age interaction on global tau PET increase in men (ADNI/A05: p = 0.0078/0.018), with younger men showing faster amyloid-associated tau accumulation. We then established patient-centered, amyloid PET-inferred tauopathy transition cut-offs. Women reached this transition at lower amyloid PET levels, and these cutoffs predicted both earlier onset and accelerated cognitive decline (p < 0.001).This study highlights the effect of age and sex on the amyloid-to-tauopathy transition, establishes patient-centered amyloid PET thresholds for tauopathy onset, and links these thresholds to accelerated cognitive decline.Younger age is related to faster amyloid-related tau accumulation in men. We defined a series of amyloid positron emission tomography (PET) thresholds to enable patient-centered inference of amyloid-related tauopathy. Crossing the amyloid PET-defined tauopathy phase is associated with more progressive tau deposition and cognitive decline.
000283122 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283122 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000283122 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283122 650_2 $$2MeSH$$aHumans
000283122 650_2 $$2MeSH$$aPositron-Emission Tomography
000283122 650_2 $$2MeSH$$aMale
000283122 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000283122 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000283122 650_2 $$2MeSH$$aFemale
000283122 650_2 $$2MeSH$$aTauopathies: diagnostic imaging
000283122 650_2 $$2MeSH$$aTauopathies: metabolism
000283122 650_2 $$2MeSH$$aAged
000283122 650_2 $$2MeSH$$atau Proteins: metabolism
000283122 650_2 $$2MeSH$$aAged, 80 and over
000283122 650_2 $$2MeSH$$aAmyloid: metabolism
000283122 650_2 $$2MeSH$$aSex Factors
000283122 650_2 $$2MeSH$$aAge Factors
000283122 650_2 $$2MeSH$$aBrain: diagnostic imaging
000283122 650_2 $$2MeSH$$aBrain: metabolism
000283122 650_2 $$2MeSH$$aCarbolines
000283122 7001_ $$aSteward, Anna$$b1
000283122 7001_ $$aDehsarvi, Amir$$b2
000283122 7001_ $$aRoemer-Cassiano, Sebastian N.$$b3
000283122 7001_ $$aDewenter, Anna$$b4
000283122 7001_ $$aBiel, Davina$$b5
000283122 7001_ $$aHirsch, Fabian$$b6
000283122 7001_ $$aFrontzkowski, Lukas$$b7
000283122 7001_ $$aPescoller, Julia$$b8
000283122 7001_ $$aKlonowski, Madleen$$b9
000283122 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b10$$udzne
000283122 7001_ $$aPontecorvo, Michael J.$$b11
000283122 7001_ $$aShcherbinin, Sergey$$b12
000283122 7001_ $$aSchöll, Michael$$b13
000283122 7001_ $$aBuckley, Rachel$$b14
000283122 7001_ $$aOssenkoppele, Rik$$b15
000283122 7001_ $$aXie, Fang$$b16
000283122 7001_ $$aGuo, Tengfei$$b17
000283122 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b18$$udzne
000283122 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b19$$udzne
000283122 7001_ $$00000-0001-9736-2283$$aFranzmeier, Nicolai$$b20
000283122 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.71064$$gVol. 22, no. 1, p. e71064$$n1$$pe71064$$tAlzheimer's and dementia$$v22$$x1552-5260$$y2026
000283122 8564_ $$uhttps://pub.dzne.de/record/283122/files/DZNE-2026-00018.pdf$$yRestricted
000283122 8564_ $$uhttps://pub.dzne.de/record/283122/files/DZNE-2026-00018.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283122 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b10$$kExtern
000283122 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000283122 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000283122 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283122 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000283122 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283122 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283122 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283122 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000283122 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x1
000283122 980__ $$ajournal
000283122 980__ $$aEDITORS
000283122 980__ $$aVDBINPRINT
000283122 980__ $$aI:(DE-2719)1111015
000283122 980__ $$aI:(DE-2719)1110007
000283122 980__ $$aUNRESTRICTED